Correlation between age and Chromogranin A determination in prostate diseases

Area of Science:

• Urology
• Oncology
• Biomarker Research

Background:

• Serum Chromogranin A (CgA) is a neuroendocrine marker.
• Its diagnostic significance in prostate diseases, particularly prostate cancer (PC), requires clarification.
• The influence of patient age on CgA levels in this context is not well understood.

Purpose of the Study:

• To evaluate the impact of age on the diagnostic significance of serum CgA in patients with prostate diseases.
• To compare the predictive performance of CgA with age and standard diagnostic tools for PC.
• To analyze CgA correlations with prognostic parameters in PC patients.

Main Methods:

• Serum CgA levels were measured in 217 consecutive patients prior to prostate biopsy.
• CgA differences between prostate cancer (PC) and benign prostatic hyperplasia (BPH) were analyzed.
• Multivariate analysis assessed CgA as a predictor of PC, comparing its performance with age and other clinical factors.

Main Results:

• Serum CgA showed a positive correlation with age in the overall patient population and in the PC subgroup.
• CgA approached statistical significance as an independent predictor of PC, but age was identified as a confounding factor.
• In PC patients, CgA did not correlate with PSA, Gleason score, or disease stage, only with age.

Conclusions:

• Age is a significant confounding factor in the interpretation of serum CgA levels for prostate diseases.
• Serum CgA is not a validated diagnostic marker for PC, but reflects neuroendocrine differentiation.
• CgA levels in untreated PC patients do not correlate with established prognostic factors, except for age.